Related Experiment Video
Updated: Jun 7, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype
Suheil Albert Atallah-Yunes1, Yucai Wang1
1Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Abstract:
The nonrandomized phase II study by Ding et al. explored the combination of azacitidine and chidamide with or without GemOx chemotherapy in relapsed/refractory peripheral T cell lymphoma and demonstrated that the dual epigenetic therapy is safe and efficacious, particularly in the angioimmunoblastic T cell lymphoma subset.1 Further investigation into adding chemotherapy is warranted, building on the promising results seen in this trial.
More Related Videos
07:39Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019
12:16A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Related Concept Videos
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...